Jim Momtazee’s Patient Square leads $150M+ addition to Kriya Therapeutics’ Series C

Shankar Ramaswamy’s Kriya Therapeutics has upped its Series C with an additional $150 million-plus to take the biotech into late 2026.

The AAV-focused gene therapy maker hopes to bring its first candidates to the clinic in the next 18 to 24 months, Ramaswamy, the co-founder and CEO, told Endpoints News….
Click here to view original post